Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

This study is testing a combination of hormone-blocking therapy (androgen deprivation) and an immunotherapy drug called pembrolizumab for people with advanced salivary gland cancer that has a specific protein called the androgen receptor. These tumors can be hormone-sensitive, and combining hormone suppression with immunotherapy may improve outcomes. **You may be eligible if...** - You are at least 18 years old - You have locally advanced, recurrent, or metastatic salivary gland cancer - Your tumor tests positive for the androgen receptor - You are in adequate health (good physical functioning) - Prior chemotherapy is allowed but not required **You may NOT be eligible if...** - Your tumor does not have the androgen receptor - You have had prior immunotherapy with checkpoint inhibitors - You have active autoimmune disease - You are pregnant or breastfeeding - You have serious heart, lung, or other organ problems Talk to your doctor to see if this trial is right for you.